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Abstract
Background: To evaluate the objective clinical outcomes of active specific immunotherapy (ASI) in advanced
colorectal cancer (advanced CRC) and suspected minimal residual colorectal cancer (suspected minimal residual CRC).
Methods: A search was conducted on Medline and Pub Med from January 1998 to January 2010 for original
studies on ASI in colorectal cancer (CRC). All articles included in this study were assessed with the application of
predetermined selection criteria and were divided into two groups: ASI in advanced CRC and ASI in suspected
minimal residual CRC. For ASI in suspected minimal residual CRC, a meta-analysis was executed with results
regarding the overall survival (OS) and disease-free survival (DFS). Regarding ASI in advanced colorectal cancer, a
system review was performed with clinical outcomes.
Results: 1375 colorectal carcinoma patients with minimal residual disease have been enrolled in Meta-analysis. A
significantly improved OS and DFS was noted for suspected minimal residual CRC patients utilizing ASI (For OS: HR
= 0.76, P = 0.007; For DFS: HR = 0.76, P = 0.03). For ASI in stage II suspected minimal residual CRC, OS approached
significance when compared with control (HR = 0.71, P = 0.09); however, the difference in DFS of ASI for the stage
II suspected minimal residual CRC reached statistical significance (HR = 0.66, P = 0.02). For ASI in stage III suspected
minimal residual CRC compared with control, The difference in both OS and DFS achieved statistical significance
(For OS: HR = 0.76, P = 0.02; For DFS: HR = 0.81, P = 0.03). 656 advanced colorectal patients have been evaluated
on ASI in advanced CRC. Eleven for CRs and PRs was reported, corresponding to an overall response rate of 1.68%.
No serious adverse events have been observed in 2031 patients.
Conclusions: It is unlikely that ASI will provide a standard complementary therapeutic approach for advanced CRC
in the near future. However, the clinical responses to ASI in patients with suspected minimal residual CRC have
been encouraging, and it has become clear that immunotherapy works best in situations of patients with
suspected minimal residual CRC.
Background
Colorectal cancer (CRC) is the third most common can-
cer in females and the fourth most common in males
worldwide. CRC is the fourth and fifth most frequent
cause of cancer-related deaths depending on gender [1].
Surgery is the cornerstone of CRC therapy. Unfortu-
nately, more than 20% of patients with CRC have meta-
static disease at the time of diagnosis [2]. Although the
most common indication for liver resection in developed
countries is metastatic CRC, surgery can only be per-
formed in 20% patients [3].The prognosis of patients
with resectable tumor depends on the disease stage. The
5-year survival for patients with CRC following surgery
varies between 80-90% for stage I, 70-75% for stage II,
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Despite the fact that 80% of CRC patients have complete
macroscopic clearance of the tumor by surgery, 50% of
CRC patients will relapse [5]. This is presumably due to
the presence of micro-metastasis at the time of surgery.
In general, the 5-year survival for patients with CRC
ranges from 50-60% over the past 30 years [6].
Avenues for the clinical testing of rationally designed
vaccination strategies, including immunotherapy, are
being explored as complementary treatments. Recent
advances in immunology and molecular biology have
opened new fronts against cancer. Early strategies used
for treatment of CRC included non-specific immu-
notherapies, such as exogenous immunostimulants,
cytokines, adoptive transfer of non-specific immune
effector cells, and the inhibition of negative immune
regulatory pathways and tumor-derived immune sup-
pressive molecules. Several studies have evaluated the
clinical results to nonspecific immunotherapies in
patients with CRC, but most of studies revealed no
improvement in the response rate, progression-free
survival, or overall survival [7-9]. In general, nonspeci-
fic approaches have yielded limited results in the treat-
ment of CRC. Since the discovery of tumor-associated
antigens during the early 1990s, rapid progress has
been made in identifying antigens and describing
immune interactions in cancer patients. Many clinical
trials have been conducted using active specific immu-
notherapy (ASI) in CRC, including autologous tumor
cell vaccines, define-tumor protein vaccines, monoclo-
nal antibodies and anti-idiotype vaccines, multi- pep-
tide vaccines, viral vector vaccine, DC vaccine, and
naked DNA vaccine[10].
However, despite an abundance of preclinical data,
relatively little is known regarding the efficacy of ASI in
CRC. Early clinical trials of ASI against CRC have pro-
vided mixed results, which led to a controversy flare-up
over the clinical efficacy of ASI in CRC [11,12]. In the
present report, we focused on meta-analysis of ASI to
patients with suspected minimal residual colorectal can-
cer (suspected minimal residual CRC), and reviewed the
objective clinical outcomes of ASI in advanced colorec-
tal cancer (advanced CRC) during the past 12 years.
Methods
Literature Search Strategy
A search was conducted on Medline and PubMed from
January 1998 to January 2010 for original studies on ASI
in CRC, Using the following keywords: “colorectal” OR
“colon” OR “rectal” AND “cancer” OR “carcinoma”
AND” vaccine “OR “vaccination” OR “immunization”.
Review papers were also examined for published results.
We avoided duplications of data by examining the body
of each publication and the names of all authors. When
such duplications were identified, the latest version was
included into our study.
Selection Criteria
Inclusion criteria included all articles concerning histo-
pathologically defined CRC treated by ASI. At the
beginning of ASI, a minimum of 4-weeks should have
elapsed from the time of completion of prior che-
motherapy and/or radiation therapy. No concurrent che-
motherapy, radiotherapy, or drugs which affect immune
function (such as glucocorticoids, Cimetidine, etc.)
should have been administered during ASI or follow-up.
Studies were limited to human trials, and in the English
language. Data regarding tumors without specific docu-
mentation of colorectal origin were not included. How-
ever, these exclusions were not applied if isolated data
regarding CRC are provided. Case studies, review arti-
cles, and studies involving fewer than three patients
were excluded to allow for consistent results.
Data Extraction and Quality Assessment
Two reviewers independently selected the trials and per-
formed the data extraction. Discrepancies were resolved
by discussion among reviewers. Because the outcome
parameters are different in advanced CRC and suspected
minimal residual CRC, we divided the articles into two
groups: ASI in advanced CRC (a measurable tumor bur-
den) and ASI in suspected minimal residual CRC (patients
had undergone complete resection for primary tumor or
metastasis disease without evidence of remaining macro-
scopic disease). Clinical outcomes to evaluate ASI in sus-
pected minimal residual CRC were OS and DFS, and
clinical outcomes of ASI in advanced CRC were complete
response (CR), partial response (PR), mixed or minor
response (MR) and stable disease (SD), which had to meet
the WHO criteria. To avoid ignoring small benefits that
could add up to a clinically relevant result, the clinical
benefit rate (CBR) has been introduced in this report. The
CBR represents the sum of CR, PR, MR, and SD rates.
Thus, for subset analysis, the CBR was calculated as the
sum of CR, PR, MR, and SD based on the various vaccine
formulations, the route of vaccination, and adjuvants [13].
For the Meta-analysis of ASI in suspected minimal resi-
dual CRC, the overall quality of each study was assessed in
accordance with the Jadad format[14]. A grading scheme
(A, B, and C) is used to classify four main aspects: 1) qual-
ity of randomization, 2) quality of allocation concealment,
3) quality of blinding, and 4) quality of the description of
withdrawals and dropouts. The grades are described as
thus: A) adequate, with correct procedures, B) unclear,
without a description of methods, and C) inadequate pro-
cedures, methods, or information. Based on these four cri-
teria, the studies could be divided into three groups. “A”
studies had a low risk of bias for studies and were scored
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of bias for studies with one or more B grades; “C” studies
had a high risk of bias and were those with one or more C
grades.
Statistical Analysis
With regards to ASI in advanced CRC, a post hoc explora-
tive analysis was performed to calculate the overall
response rate of ASI as well as the clinical benefit rate,
based on the various vaccine formulations, the route of
vaccination, and adjuvants. For the ASI in suspected mini-
mal residual CRC, statistical analysis was carried out using
Review Manager (version 5.0) provided by The Cochrane
Collaboration. Dichotomous data were presented as rela-
tive risk (HR) and continuous outcomes as weighted mean
difference (WMD), both with 95% confidence intervals
(CI). The overall effect was tested using Z scores, with sig-
nificance being set at P < 0.05. Meta-analysis was per-
formed using fixed-effect or random-effect methods,
depending on absence or presence of significant heteroge-
neity [15]. Statistical heterogeneity between trials was eval-
uated by the chi-squared and I square (I
2)t e s t s ,w i t h
significance being set at P < 0.10. In the absence of statisti-
cally significant heterogeneity, the fixed-effect method was
used to combine the results. When heterogeneity was con-
firmed (P ≤ 0.10), the random-effect method was used.
Results
Quantity of Evidence
A total of 789 studies were identified by the searches. By
scanning titles and abstracts, 548 redundant publications,
reviews and case reports were excluded. After referring
to full texts, 192 studies which did not satisfy the inclu-
sion criteria were removed from consideration. A total of
49 studies were left for analysis which involved 2031
patients, of whom 1375 (6 studies) were included in ASI
for suspected minimal residual CRC group, and 656 (43
studies) were included in ASI for advanced CRC group.
Table 1 shows the characteristics of the six trials
included in the meta-analysis [16-21]. Three of the six
trials reported data for 7 years follow-up, other three
studies followed up for 1 year, 5 years and 7.6 years
respectively. All six studies were randomized, three stu-
dies mentioned the concealment of allocation clearly in
the randomization process, and two studies mentioned
withdrawal rates; however, none of the trials was
blinded. Accordingly, we considered two studies as cate-
gory B, and four as category C.
Table 2 shows the characteristics of the 43 trials
included in ASI for advanced CRC group [22-64].
Among 43 studies, all had clearly stated inclusion and
exclusion criteria. In addition, all studies were described
with comparable baseline characteristics of ASI, includ-
ing the number of evaluated CRC patients, the type of
vaccine, the route of vaccination, adjuvants, the toxicity,
and the objective clinical responses.
Meta-analysis of ASI in suspected minimal residual CRC
The OS at the end of treatment for ASI in patients with sus-
pected minimal residual CRC is shown in Table 1. For stage
I-IV suspected minimal residual CRC, statistically significant
heterogeneity was detected (Tau2 = 0.03, Chi2 = 11.13,
Table 1 Clinical trials of ASI in suspected minimal residual CRC
Ref ASI Stage of patient Overall Survival Disease-free Survival Follow up Jadad’s grades
No. of events/no. of subjects (year)
[21] ATC Stage II Con:31 of 109 Con:35 of 109 7.6 B
Exp:16 of 73 Exp:18 of 73
Stage III Con:26 of 44 Con:28 of 44
Exp:15of 33 Exp:15 of 33
[22] ATC-BCG Stage II Con:21 of 77 Con:29 of 77 5 C
Exp:14 of 80 Exp:17 of 80
Stage III Con:12 of 40 Con:17 of 40
Exp:16of 44 Exp:20 of 44
[23] ATV-NDV Stage I-IV Con:16 of 25 NO 7 C
Exp:12of 25
[24] 17-1 Stage III Con:48 of 76 Con:54 of 76 7 B
Antibody Exp:39 of 90 Exp:50 of 90
[25] ATC Stage I-IV Con:146 of 257 NO 7 C
Exp:135 of 310
[26] ATC Stage IV Con:48 of 50 NO 1 C
Exp:20 of 42
Abbreviations: Ref, reference; ASI, active specific immunotherapy; Con, control group; Exp, ASI experiment group; ATC, antilogous tumor cells; NDV, newcastle
disease virus; No, not done.
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effect method for meta-analysis. HR for ASI in stage I-IV
suspected minimal residual CRC was 0.76 (95% CI 0.63-
0.93), the difference of OS at the end of follow-up between
the ASI in stage I-IV suspected minimal residual CRC group
and control groups was statistically significant (Z = 2.68, P =
0.007) (Figure 1).
For stage II or III suspected minimal residual CRC,
There were no statistical heterogeneity (Heterogeneity
for stage II: Chi2 = 0.20, df = 1, P = 0.65, I2 = 0%; for
Table 2 Clinical trials of ASI in advanced CRC
Ref Vaccine Adjuvant Route Patients CR+PR MR SD
[27] Anti-Id 3H1 i.c AH 23 0 0 NR
[28] CEA/HbsAg-CMV i.m HBsAg 17 0 0 0
[29] DC-CEA peptid i.v No 10 1 1 2
[30] ALVAC(CEA-B7.1) i.m ALVAC/B7.1 13 0 0 2
[31] DC-CEA peptid i.v No 7 0 0 1
[32] Auto-tumor i.d NDV 13 4 0 8
[33] DC-CEA peptid i.t No 10 0 0 2
[34] Virus CEA s.c GM-CSF\IL-2 11 0 0 NI
[35] Virus CEA i.d/s.c Tricom/GM-CSF 35 0 0 14
[36] DC-CEA peptid s.c No 7 0 0 2
[37] SART3 peptide s.c IFA 12 0 0 1
[38] DC-CEA transfected i.v+id IL-2 11 0 0 0
[39] DC-CEA peptid s.c+id Tricom 11 0 0 6
[40] DC + tumor RNA i.v KLH 15 0 0 0
[41] DC+MAGE3 peptide i.v No 3 0 1 0
[42] SART-IcK-CyB multi peptide s.c Montanideisa-51 10 0 1 1
[43] Survive peptide s.c No 17 0 1 3
[44] DC + CEA peptide s.c/i.d No 11 0 0 3
[45] ALVAC expressing CEA+B7.1 i.d B7.1 28 0 0 7
[46] Autologous hemoderivative s.c GM-CSF 50 0 0 26
[47] DC+allogeneic tumor cell lysate i.d No 17 0 0 4
[48] TroVax i.m MVA 17 0 0 5
[49] P53-SLP s.c No 10 0 0 4
[50] tumor lysate pulsed-Dc i.t THI 8 0 0 4
[51] Aex+GM-CSF s.c GM-CSF 20 0 1 1
[52] DC+MHC-I peptide i.d IFN-[r]/GM-CSF 11 0 0 0
[53] Glutaraldehyde-fixed HUVECs i.d No 3 0 0 0
[54] Xenogenic polyantigenic vaccine s.c IL-2 37 2 10 11
[55] Oncolytic poxvirus JX-594 PEIT GM-CSF 4 0 0 3
[56] MIDGE s.c d-SLIM 10 2 1 2
[57] ALVAC-p53 i.v ALVAC 16 0 0 1
[58] ONYX-015 adevirus i.v No 18 0 0 7
[59] TNFa AutoVaccIne i.m AH 33 2 0 7
[60] rF-CEA-TRICOM i.d B7.1 11 0 1 4
[61] CEA alt-plused DC iv No 7 0 0 1
[62] DC-CEA peptid i.t IL-4/GM-CSF 10 0 0 2
[63] Murine monoclonal CEA-antibody i.d AH 15 0 0 1
[64] Ep-CAM protein s.c MPL/GM-CSF 11 0 0 3
[65] Vaccine virus expressing CEA i.d/s.c No 20 0 0 2
[66] DC + CEA peptide i.v/i.d IL-2 11 0 0 0
[67] Antibody SCV 106 mimicking 17-1A s.c AH 21 0 0 0
[68] Autologous tumor s.c Fibroblasts/IL-2 10 0 0 1
[69] retroviral vector- IL-2 allogeneic tumor cells + IL-1a i.d DETOX/IL-1a 22 0 2 0
Total 43 656 11(1.68%) 19(2.9%) 141(21.49%)
Abbreviations: Ref, reference□AH: aluminum hydroxide; NI, not identifiable; NR, not Reported; DC, dendritic cells□NDV, newcastle disease virus; IL, interleukin;
ß-HCG, ß-human chorionic gonadotropin; THI,tetanustoxoidntigen/hepatitis B/influence matrix peptide; IFA, incompleteFreund’s adjuvant.
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use of a fixed effect model for meta-analysis (Figure 2, 3). HR
for stage II was 0.71 (95% CI 0.48-1.06, Z = 1.69, P = 0.09)
(Figure 2), and HR for stage III was 0.76 (95% CI 0.61-0.96,
Z = 2.32, P = 0.02) (Figure 3). For ASI in stage II suspected
minimal residual CRC, OS approached significance (P =
0.09) when compared with control; however, the difference
in OS of ASI for the stage III suspected minimal residual
CRC reached statistical significance.
The DFS of the patients in three studies at the end fol-
l o w - u pi ss h o w ni nt a b l e1 .T h ese included 666 patients
and showed the HR for DFS in stage II and stage III sus-
pected minimal residual CRC was 0.76 (95% CI 0.59-0.97,
Z = 2.23, P = 0.03) (Figure 4), which showed ASI in stage
II and stage III suspected minimal residual CRC was
markedly effective in term of DFS. No statistical hetero-
geneity was found (Chi2=0.00, df=1, P=0.99, I2=0%)
(Heterogeneity for stage II-III suspected minimal residual
C R C :C h i 2=0 . 0 0 ,d f=1 ,P=0 . 9 9 ,I 2=0 % ;f o rs t a g eI I
Chi2 = 0.74, df = 1, P = 0.39, I2 = 0%; for stage III: Chi2
=1 . 6 7 ,d f = 2 ,P=0 . 4 3 ,I 2=0 % )( F i g u r e4 ,5 ,6 ) ,a l l o w i n g
the use of a fixed effect model for meta-analysis. The HR
for DFS in stage II suspected minimal residual CRC was
0.66 (95% CI 0.47-0.94, Z = 2.29, P = 0.02) (Figure 5),
compared to a 0.81 HR in stage III suspected minimal
residual CRC (95% CI 0.67-0.97, Z = 2.22, P = 0.03) (Fig-
ure 6). The results revealed that ASI in stage II suspected
minimal residual CRC was more effective than in stage
III suspected minimal residual CRC in term of DFS.
Assessment of ASI in advanced CRC
For analysis of ASI in advanced CRC, 656 patients were
evaluated for clinical responses. Eleven patients reported
CR and seventeen reported PR, out of a total population
of 656 patients, which corresponded to an overall
response rate of 1.68%. MR was reported in 2.90% of
patients; SD was found in 21.49%. The combined per-
centages of CR, PR, MR, and SD for all patients yielded
a CBR of 26.07% (Table 2).
In 43 studies of ASI in advance CRC, patients received
a variety of vaccinations including dendritic cells in
fourteen studies, viral vector vaccines in ten, peptide in
eight, autologous or allogeneic tumor cells or tumor-
derived products in five, monoclonal antibodies and
anti-idiotype vaccines in four, and other substances in
five studies (naked DNA vaccine, define-tumor protein
vaccine, autologous hemoderivative cyclophosphamide,
glutaraldehyde-fixed HUVECs and xenogenic polyanti-
genic vaccine). CBR of 45/142 (31.7%) for multi-peptide
vaccines, 17/70 (28.6%) for autologous tumor cell vac-
cine, 46/163 (28.2%) for viral vector vaccine, 30/134
(22.4%) for dendritic cell-based vaccines (Table 3).
Despite the broad variety of antigens described, carci-
noembryonic antigen-based vaccination was used in 18
Figure 1 Forest plot of comparison: Overall Survival of 6 included study (stage I-IV).
Figure 2 Forest plot of comparison: Overall Survival of stage II (2 study).
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SD were reported in a total population of 256 patients
(CBR = 20.3%). Fifteen further substances were used as
adjuvants, Ten studies were done without adjuvants. Vac-
cines were administrated by different routes of injection: s.
c. in ten studies, i.d. eight studies, i.m. five studies, i.v. four
studies, i.d. and s.c. five studies, i.v. and i.d. three studies,
and intralymphatic/intranodal two studies. In a post hoc
analysis, The CBR ranged between 19.7% and 34% regard-
less of the route of vaccination (Table 4).
Assessment of Toxicity for ASI in CRC
The current clinical experience with ASI does not indi-
cate considerable toxicity. Neither short-term serious
adverse events nor long-term autoimmune side effects
have been observed using therapeutic vaccines in a large
number of patients. The most frequently reported
adverse events causally related to the use of ASI were
mild (grade 1-2) in severity, including injection site reac-
tions (e.g, erythema, pruritus, pain), fever, nausea, and
fatigue. There were no significant hepatic, renal, pul-
monary, cardiac, hematologic, or neurologic toxicities
attributable to the treatments. No clinical manifestations
of autoimmune reactions were observed. No significant
changes in temperature and blood pressure were
recorded. Other side effects include rare cases of adeno-
pathy, diarrhea, rigors, malaise, and transfusion-like
reactions. All other symptoms were described only in
single cases and/or are most probably due to the
advanced malignant disease or a side effect of adjuvants.
Discussion
According to our Meta-analysis, all patients with sus-
pected minimal residual CRC who met quality control
specifications and protocol eligibility (analyzable
patients), OS (P = 0.007), and DFS (P = 0.003) were sig-
nificantly improved when compared with controls. A
subgroup analysis by stage of disease, For ASI in stage II
suspected minimal residual CRC compared with control,
OS approached significance when compared with con-
trol (P = 0.09), The DFS of ASI reached statistical signif-
icance (P = 0.02); For ASI in stage III suspected minimal
residual CRC compared with control, The difference in
both OS (P = 0.02) and DFS (P = 0.03) achieved statisti-
cal significance. These results indicated ASI may provide
a new promising targeted therapeutic approach in sus-
pected minimal residual CRC.
The efficacy of ASI in patients with suspected minimal
residual CRC is encouraging and merit generalization in
colorectal cancer therapy based on three reasons. First,
in less than a decade, because of improved diagnostic
methods, there has been a major shift from stage IV to
stage II CRC. In 1995, stage IV disease accounted for
approximately 50% to 55% of all cases, stage III
accounted for 30%, and stage II for less than 20%. For
the year 2004, it is estimated that stage IV cancers will
account for approximately 10% of all cases, while stage
II disease will rise to 40% of all cases [65]. This progres-
sion is expected to continue through the rest of the dec-
ade, which means more and more CRC patients would
procure benefits with ASI. Second, micro metastases are
Figure 3 Forest plot of comparison: Overall Survival of stage III.
Figure 4 Forest plot of comparison: Disease-free Survival of 3 study (Stage II and stage III).
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eventual death of CRC patients. Occult micro metas-
tases or suspected minimal residual CRC have been
detected in lymph nodes or in the operating field in
54% of stage II patients. Analysis of the relationship
between PCR-detectable metastases and survival has
resulted in an adjusted five year survival of 91% in
patients without minimal residual CRC and 50% in
patients with minimal residual CRC, with observed five
year survival rates of 75% and 36%, respectively [66].
Hence, the development of new methods of treatment
to eliminate micro metastases in patients with suspected
minimal residual CRC and thereby delay or prevent
recurrence is particularly urgent given the increasing
incidence of CRC. Third, cancer stem cells may be
responsible for tumor recurrence and metastatic lesions,
and have been postulated to be a very small population
of quiescent or very slowly dividing cells within a grow-
ing tumor mass. Such cells would be inherently resistant
to treatments such as chemotherapy, which target prolif-
erating cells [67]. Since the proliferation is not a prere-
quisite for recognition and destruction by the immune
mechanisms, ASI may be the most effective way to elim-
inate cancer stem cells, ASI is likely to be applied in the
setting of curatively minimal residual cancer with the
goal of clearing the invisible but present cancer burden.
The efficacy of ASI in patients with advanced CRC
was disappointed. Nagorsen et al evaluated the out-
comes of ASI in advanced CRC from January 1985 to
January 2006, which revealed a very weak clinical
response rate of 0.9% for ASI procedures available for
advanced CRC [13]. In the present system review, we
found an objective response rate of 1.68% over 656
advanced CRC patients treated with ASI in 43 different
studies. Peptide vaccination had the highest CBR of
31.7%, followed by 28.6% for autologous tumor vaccines,
28.2% for viral vector vaccine, and 24.4% for DC-based
therapy. These data are two-fold higher than those
reported by Nagorsen et al. Our study has demonstrated
that ASI in CRC has made recent progression.
However, although progression was conspicuous with
ASI in advanced CRC, the clinical results are still limited.
As new generations of vaccines are developed to improve
the clinical efficiency, several considerations will require
attention. First, because chemotherapy is standard in the
treatment of CRC, it is important to demonstrate
whether immunizations may be given to patients who are
receiving systemic chemotherapy. This opportunity rests
in strategically combining immunotherapies with both
traditional and novel cancer drugs to shape both the glo-
bal host environment and the local tumor environment,
and to ameliorate distinct layers of immune tolerance,
ultimately supporting a vigorous and sustained antitumor
immune response [68]. Within this modified host envir-
onment, ASI regimens that (1) combine tumor vaccines
or tumor-specific lymphocytes with targeted drugs that
amplify the magnitude and quality of end immune effec-
tors and (2) relieve the normal controls at specific points
in the process of T cell activation will be critical for suc-
cess [69]. More importantly, chemotherapeutic drugs kill
Figure 5 Forest plot of comparison: Disease-free Survival of stage II.
Figure 6 Forest plot of comparison: Disease-free Survival of stage III.
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tumor antigens that are presented to immune system.
Moreover, the process of apoptotic cell death may in
itself provide an immunostimulatory signal. Both have
the capacity to enhance antitumor immune responses.
Second, ASI effectiveness depends on tumor burden. An
advanced cancer actually induces Tregs and then uses
them to subvert the immune response of ASI [70]. The
implication is that the Tregs contribute to the inability of
immune system to eliminate the growing tumor. It is
thus apparent that effective ASI should include
approaches that target Tregs in vivo. Several strategies
have been employed with certain efficacy in cancer,
including depletion with anti-CD25 antibodies, treatment
with anti-GITR and anti-CTLA-4 [71-73]. The findings
suggest depletion Tregs may be used in the future to
improve immunotherapy in CRC [74]. Third, it may be
more important to choose antigens that have functions
important to the cancer cell. Some researchers have
argued that immunologically targeting proteins without a
known protumorigenic function may ultimately fail
because tumors could down-regulate these antigens with-
out a detrimental effect to their function [75]. As new
generations of vaccines are developed, DNA vaccination
is a promising avenue for the development of a successful
CRC vaccine [76]. However, there is only one clinical trial
which utilizes a DNA vaccine for CRC [22]. We agree
with those who find it premature to give up on active
cancer vaccines, although much work remains.
Conclusions
In summary, This Meta-analysis and System Review
clearly supports the idea that a statistically significantly
i m p r o v e dD F So rO Sw a ss h o w ni na l ls t a g es u s p e c t e d
minimal residual CRC patients. Meanwhile, there was
also a clear indication that the objective clinical outcome
of ASI in advanced CRC was only 1.6%. The results
showed it is unlikely that ASI will provide a standard
complementary therapeutic approach for advanced CRC
in the near future. However, it has become clear that
immunotherapy works best in situations of patients with
suspected minimal residual CRC.
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